BioNTech co-founders Özlem Türeci (L) and Uğur Şahin (Horst Galuschka/picture-alliance/dpa/AP Images)

June 5, 2022 12:30 PM EDTUpdated June 6, 08:27 AM

#ASCO22: BioNTech says mRNA vaccine safe in 15 of 16 patients with deadly pancreatic cancer

Kyle LaHucik

Senior Reporter

CHICAGO — Pandemic vaccine breakout BioNTech is back with more data on its individualized mRNA cancer jab known as autogene cevumeran in the most common …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ASCO22: BioNTech says mRNA vaccine safe in 15 of 16 patients with deadly pancreatic cancer

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

#AS­CO22: BioN­Tech says mR­NA vac­cine safe in 15 of 16 pa­tients with dead­ly pan­cre­at­ic can­cer

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

#ASCO22: BioNTech says mRNA vaccine safe in 15 of 16 patients with deadly pancreatic cancer

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?